 Kazia Therapeutics Ltd has received an increased target price share from Edison Group, rising to A2.83 from A2.68 a share following the release of interim data for its 30-patient Phase II trial of paxalisib in newly diagnosed glioblastoma multiforme GBM patients. Final data from the trial as well as initial data for paxalisib in the treatment of brain metastases BMs is expected before the end of this year. 